Cartesian Therapeutics, Inc. announced the enrollment of the first participant in its Phase 3 AURORA trial of Descartes-08 for patients with myasthenia gravis (MG). This milestone marks a significant advancement in the clinical development of the company's lead cell therapy candidate.
The Phase 3 AURORA trial is designed as a randomized, double-blind, placebo-controlled study, evaluating Descartes-08 versus placebo in approximately 100 participants with acetylcholine receptor autoantibody positive MG. The primary endpoint will assess the proportion of Descartes-08 participants achieving an improvement of three points or more in their MG Activities of Daily Living (MG-ADL) score at Month 4.
Descartes-08 is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy designed for outpatient administration without preconditioning chemotherapy. The initiation of this pivotal trial follows compelling 12-month data from the Phase 2b trial, which demonstrated sustained benefits and an average 4.8-point reduction in MG-ADL at Month 12 after a single course of therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.